Influence on erythropoietin levels of treatment with cisplatinum-endoxan

W Lechner; E Artner-Dworzak; E Sölder; M Sachsenmaier; D Kölle; H Moncayo; R Reitsamer

doi:10.1007/BF02389607

Influence on erythropoietin levels of treatment with cisplatinum-endoxan

Arch Gynecol Obstet. 1992;252(1):49-53. doi: 10.1007/BF02389607.

Authors

W Lechner¹, E Artner-Dworzak, E Sölder, M Sachsenmaier, D Kölle, H Moncayo, R Reitsamer

Affiliation

¹ Department of Obstetrics and Gynecology, University of Innsbruck, Austria.

PMID: 1417088
DOI: 10.1007/BF02389607

Abstract

Erythropoietin levels have been determined in 24 patients with different gynecologic malignancies, who were treated with cisplatinum and endoxan. A statistically highly significant decrease was demonstrated 2 h after starting treatment with a further significant decrease at 6 h. After 12 h the erythropoietin concentrations returned to values similar to those before treatment started.

MeSH terms

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Cisplatin / administration & dosage
Cisplatin / adverse effects
Cyclophosphamide / administration & dosage
Cyclophosphamide / adverse effects
Erythropoietin / blood*
Female
Genital Neoplasms, Female / blood
Genital Neoplasms, Female / drug therapy*
Humans
Middle Aged

Substances

Erythropoietin
Cyclophosphamide
Cisplatin